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INTRODUCTION
Severe sepsis and trauma are associated with protein catabolism, negative
nitrogen balance and immunosuppression and represent a major threat to
survival. Nutritional supportinthesecircumstancesmaintainsnitrogen balance
and reduces both mortality and morbidity.1-4 However catabolism associated
with sepsis is not reversed by standard hyperalimentation formulations.5 There
is evidence that individual amino acids, used in pharmacological doses, may
modify metabolism and modulate immune function during sepsis. Examples of
such amino acids include, leucine, isoleucine and valine (branched chain
amino acids) which inhibit muscle protein catabolism,6 glutamine which
improves gutimmunefunction7 andargininewhichenhancessystemic immune
function.8 This review will concentrate on the metabolic effects of L-arginine,
its significance as a substrate for nitric oxide synthesis and its potential as a
pharmacological agent.
ARGININE IN HEALTH
Nutrition - Arginine is a dibasic nitrogen-rich molecule and although it can be
synthesizedendogenously in manymammals includinghumans,9 viathe Krebs
cycle, most is obtained from the diet. It shares an active transport system (y+)
withotherbasic aminoacids (lysine, ornithine andcystine) forabsorption inthe
small intestine and there is also an active uptake mechanism within the kidney
preventing excretion. Liver and kidney are both capable of synthesizing
arginine from citrulline and ornithine via the urea cycle and by the same
mechanism supply of arginine can control the synthesis of other amino acids
(Figure 1). The liver has a relatively high concentration ofthe enzyme arginase
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(which degrades arginine into urea and ornithine), whereas renal arginase
activity is low. The kidney therefore is the primary organ for conserving
arginine.10
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carbamyl
phosphate
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Figure 1 Krebs-Henseleit urea cycle
In health dietary arginine is not required for maintainance ofnitrogen balance,
but during growth or in illness and stress endogenous synthesis from citrulline
is insufficient to meet body demands.""12 Thus arginine has been described as
a semi-essential amino acid. In contrast, in vitro, arginine is an essential amino
acid for cell culture systems'3 and is an essential precursor for polyamine,
histone and nucleic acid synthesis which in turn are required for mitosis and
manufacture of cellular proteins.
Secretagogue effects - Arginine is the most potent amino acid stimulator of
insulin secretion when given either orally or intravenously.'4 There is however
only a minor fall in plasma glucose concentrations due to simultaneous
stimulation ofgrowth hormone production.'5 Arginine also increases secretion
of prolactin,16 glucagon, pancreatic pancreozymin,17 pancreatic polypeptide
and adrenal catecholamine'8 but thte importance of these secretory pathways
is not fully understood.
Immunological effects - In vivo - Supplemental dietary arginine increases
thymocyte production and thymic weight in healthy animals.'9 Thymocytes
from these animals show increased proliferative responses to the mitogens
phytohaemagluttinin andconconavalinA.20Thiseffectisnotnoted in surgically
or medically hypophysectomised animals suggesting that the hypothalamic/
pituitary axismayberesponsibleforsome ifnotallofthe invivoimmune effects
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of arginine. In athymic nude mice arginine improves T cell function (as
assessed by delayed type hypersensitivity responses) indicating that it can
exert its effects on peripheral lymphocytes and not just those within the
thymus.21 Arginine by improving host immunity enhances rejection of skin
allografts in mic.22 In vitro - T lymphocytes taken from healthy animals and
humans given pharmacological doses of arginine show increased blastogenic
responses to mitogens23-25 and also demonstrate an increase in the T helper to
T suppressor cell ratio.26 Arginine has also been shown to be essential for
maximal generation and activation of cytotoxic T cells and natural killer (NK)
cells.27 Neutrophilsandmacrophages utiliseargininespecificallyforproduction
ofnitric oxide andstimulation ofbothcelltypesincreases nitricoxidesynthesis.
Depletion ofarginine from cell culture medium decreases the cytolytic activity
of activated macrophages and similarly the microbiostatic and tumouristatic
effectsofmacrophages aredependentonnitricoxideastheeffectormolecule.28'29
nitric
L-arginine oxide ,Nitric + L-Citrulline
synthase oxide
NO2- + NO3-
Figure 2 - Arginine /nitric oxide pathway - showing production of nitric
oxide from L-arginine with L-citrulline as the major co-product and nitrite
(NO2-) and (NO3-) as by-products.
Nitric oxide (NO) - This labile bioregulatory molecule is synthesized by many
cell types from L-arginine with L-citrulline as the major co-product (Figure 2).
It is highly lipophilic and therefore rapidly traverses cell membranes making it
an effective intra- and inter-cellular messenger. It has a very short half-life (3-
9 seconds) and must be produced in large quantities or over long periods to
have prolonged biological effects.30 When produced by cells such as
macrophages it can rapidly enter microorganisms and tumour cells and exert
cytostatic and cytotoxic effects by increasing cyclic-GMP synthesis and
inhibiting host mitochondrial electron transport and DNA replication.3' 32
Induction ofnitric oxide synthesis has also been demonstrated in neutrophils33
and cloned T lymphocytes34 but its role in cellular immunological activity is
uncertain.
ARGININE IN DISEASE
Following major surgery, trauma and sepsis normal intra- and extracellular
amino acidhomeostasis isderanged, with consequentimpairmentofmetabolic
and physiological responses. There is decreased intestinal absorption of
arginine duringsepsis35andfollowing resuscitationfromhaemorrhagic shock.36
Plasma concentrations ofarginine are low in sepsis and show a strong negative
correlation with survival.37 In children with severe burns serum arginine
concentrations are decreased and are associated with depressed immune
function.8
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Effectsofarginineinexperimentalmodels-Invariousanimalmodelsintervention
with arginine supplementation results in improved biological and immune
parameters and increased survival.
Sepsis - parenteral administration of arginine both before and after caecal
ligation and puncture results in increased survival compared with controls.38
Oral supplementation in established acute peritonitis does notconferincreased
survival39whichmaybeduetosepsis-inducedgastrointestinal malabsorption.5'36
Trauma and burns - a diet supplemented with 1% arginine improves nitrogen
balance and enhances wound healing in rats assessed by increased wound
breaking strength and collagen content.19 There is an associated reduction in
thymolysiswhichisdependentonanintacthypothalmic/pituitary axis. Arginine
reducesnitrogen lossandabrogatesthymolysis andTcell dysfunctionfollowing
unilateral or bilateral femoral fractures.20'40'4' Supplemental arginine increases
delayed type hypersensitivity reactions and bacterial containment in guinea
pigs with 30% full thickness burns.42 In this burn model there is also increased
resting metabolic expenditure on diets supplemented with 1% and 2% arginine.
Jaundice - obstructive jaundice results in impaired immune function with
increased susceptibility to infection. Dietary supplementation with arginine
following ligation ofthe common bile duct resulted in improved T cell function
assessed by delayed type hypersensitivity reactions43 and decreased mortality
following subsequent caecal ligation and puncture.44
Malignancy - supplemental dietary arginine has inhibitory effects on many
types of transplanted or chemically induced experimental tumours. In vivo
arginine reduces the incidence, increases latency, decreases growth and
metastatic spread, and improves survival in animals with tumours.45-49 These
effects of arginine are associated with increased macrophage phagocytosis48
and some if not all of the effects may be dependent on the production of nitric
oxide by immune cells.50'5' Tumours in rodents supplemented nutritionally with
arginine are more susceptible to chemotherapy than those in protein depleted
animals.52 53 These arginine effects are however dependent on the type of
tumour present, as protein depleted animals with poorly immunogenic tumours
do not respond as well as those with an obvious immune response.54
Inflammatory bowel disease - the study of malnutrition, and the immune
system dysfunction in inflammatory bowel disease has stimulated interest in
the therapeutic effects of dietary supplementation using various amino acids
including arginine, glutamine and the branched-chain amino acids. Recent
evidence suggests thatthere is increased mucosal nitric oxide synthase activity
in inflammatory bowel disease55 butthe pathophysiological role ofthis remains
uncertain. Using an animal model with many ofthe local and systemic features
of Crohn's colitis,56 and with increased nitric oxide synthase activity,57 the
involvement of nitric oxide in the disease process has been investigated.
Supplemental 2% arginine in drinking water increases the severity ofcolitis with
subsequent weight loss, thymolysis and splenolysis. This proinflammatory
effectofarginine onthecolonic mucosa is blocked by addition ofthe nitric oxide
synthase inhibitor L-NAME (lOOmg/l) to the drinking water.58 Similar research
using a model of ileitis has demonstrated a reduction in inflammation and
mucosal nitrite production following inhibition of nitric oxide synthesis.59 This
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would suggestthatnitric oxide is a majormediatorinthemucosal inflammatory
process and that its proinflammatory effects are increased by additional
arginine in the diet.
CLINICAL APPLICATIONS OF L-ARGININE
The anticatabolic and immunostimulatory effects of arginine in cell culture
systems and animal models have suggested that arginine has potential as a
therapeutic agent in various clinical situations. Disadvantages of oral arginine
treatment include its distinctive bitter taste, and increased gastrointestinal
water excretion with resultant diarrhoea.
Healthy Volunteers - in healthy humans, as in animal studies, oral arginine
supplementation increasesperipheral bloodlymphocytemitogenesis, decreases
the number of T suppressor/cytotoxic cells and increases the T helper to T
suppressor cell ratio.24 The delayed type hypersensitivity response 24, 60 iS
increased as is the number of circulating NK and lymphokine-activated killer
cells.6'
Sepsis and Trauma - parenteral administration of arginine (500mg/kg/day)
improves nitrogen balance and reduces protein catabolism secondary to
surgery and sepsis.62 In these situations arginine also helps maintain the urea
cycle with a resultant reduction in ammonia toxicity.63 In patients with the
acquired immune deficiency syndrome arginine improves T cell mitogenesis
and the T helper/suppressor ratio, but so far this has not been shown to confer
increased protection against the effects of the viral infection.8 In addition to
reducing catabolism, supplemental arginine prevents reduction in lymphocytic
immune responseanddecreaseinThelpercell occurring inpatients undergoing
major abdominal surgery.8'60Arginine therapy also improves wound healing25
and reduces the length of stay in hospital following major cancer surgery.60
Malignancy - inwomen with breastcancersupplemental arginine increasesthe
quantity and cytotoxic capability of circulating NK and lymphokine activated
cells.64 However in apparent contrast to animal and in vitro studies arginine
appears to stimulate cell growth by stimulating protein synthesis within the
tumour substance.65 This paradox may be therapeutically beneficial and may
be due to an increased lymphocytic infiltrate in such tumours. Furthermore this
enhanced tumour growth might suggest increased cell sensitivity to chemo or
radio-therapy.
Combined therapies - Recently clinical studies have included arginine as one
componentofenteral dietarysupplementation.66 67Thecombinationofarginine,
ribonucleic acid and short chain fatty acids improves blastogenic responses in
peripheral blood lymphocytes from intensive care patients and those with
gastrointestinal malignancies. In these studies postoperative infection was
reduced, wound healing was improved and there was a significant decrease in
the duration of stay in hospital.
CONCLUSIONS
Arginine is a semi-essential amino acid in health but becomes essential during
periodsofgrowth, illnessorstress. In addition argininegiven in pharmacological
doses enhances hormone secretion and is a potent modulator of immune
system function. By enhancing T lymphocyte function it improves wound
e The Ulster Medical Society, 1994.
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healing and the immune response to sepsis in experimental animals and
humans. In animal models and in cell culture systems arginine increases
macrophage activity against microorganisms and tumour cells. Therefore
supplemental arginine may be ofvalue in patients undergoing majorsurgery or
following trauma and sepsis. Although more information is required arginine
treatmentmayenhanceadjuvantchemotherapyandradiotherapyinmalignant
disease.
An arginine/nitric oxide pathway has been demonstrated in most cells of the
immune system, and nitric oxide may be the bioactive molecule by which
arginine has its immune effects. Nitric oxide has important homeostatic roles,
but increased production by immune cells may result in pathophysiological
changes in conditions such as inflammatory bowel disease. In these conditions
where increased production of nitric oxide is detrimental and stimulates the
inflammatory process, systemic and topical administration of nitric oxide
inhibitors may have therapeutic potential.
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